12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

HistoRx, Yale University deal

The university granted HistoRx rights to an assay that identifies melanoma patients who have a 40% risk of recurrence...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >